Research programme: recombinant glucosylceramidase - JCR Pharmaceuticals/GlaxoSmithKline

Drug Profile

Research programme: recombinant glucosylceramidase - JCR Pharmaceuticals/GlaxoSmithKline

Alternative Names: JR-101

Latest Information Update: 12 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JCR Pharmaceuticals
  • Developer GlaxoSmithKline KK; JCR Pharmaceuticals
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gaucher's disease

Most Recent Events

  • 12 Aug 2016 Preclinical development is ongoing for Gaucher's disease in Japan (JCR Pharmaceuticals pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gaucher's-disease in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top